Featured Research

from universities, journals, and other organizations

Anthrax Toxin Inhibitor Identified; Findings Could Lead To More Effective Therapy For Deadly Agent

Date:
December 30, 2003
Source:
Harvard Medical School
Summary:
A research team led by scientists at Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School (HMS) has identified a group of small molecules that inhibit a deadly toxin associated with inhalational anthrax.

BOSTON -- A research team led by scientists at Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School (HMS) has identified a group of small molecules that inhibit a deadly toxin associated with inhalational anthrax. Described in the January 2004 issue of Nature Structural & Molecular Biology, these findings could eventually lead to the development of a protease inhibitor drug, which in combination with antibiotics could be used to treat anthrax cases later in the disease, at a point when antibiotics alone are no longer effective.

Related Articles


"Unlike most types of bacteria, Bacillus anthracis has the ability to produce large amounts of a toxin that can kill the patient even after antibiotics have destroyed the bacteria," explains the study's senior author Lewis Cantley, Ph.D., Chief of the Division of Signal Transduction at BIDMC and Professor of Systems Biology at HMS. "This toxin is released within days of the initial infection, and is impervious to antibiotics." Because the initial symptoms of the disease – fever, cough and chest pain – mimic colds and flu, early diagnosis is extremely difficult; as a result, some 90 percent of all cases of inhalational anthrax prove fatal.

"Toxins act in two ways," adds BIDMC scientist and first author Benjamin Turk, Ph.D. "First, they cripple the cells that fight bacterial infection, thereby enabling the spread of bacteria early in the disease. Later in the process," he adds, "they contribute to the death of macrophage cells, leading to the shutdown of the body's immune system." In fact, autopsies of patients who have died from inhalational anthrax reveal that the high doses of antibiotics have killed the bacteria, indicating that the patients have died from the toxins rather than a persistent infection.

Using a "mixture-based peptide library" technique developed by Turk, the researchers analyzed trillions of peptides to determine an optimal peptide substrate for lethal factor, the active agent in the anthrax toxin. Based on the structure of the optimal substrate, small molecule inhibitors were identified. Finally, crystal structures of lethal factor protease bound to its optimal substrate and to small molecule inhibitors revealed new approaches to enable the design of better inhibitors that might prove effective for clinical use.

The mechanism by which anthrax lethal factor kills human cells is not yet clear. The protease activity of this toxin is known to attack a family of protein kinases called map kinase kinases (MEKKs), which mediate many cellular responses, including cytokine release and cell survival. The availability of drug inhibitors may facilitate the understanding of the effect of lethal factor on these pathways. Protease inhibitor drugs have gained popularity in recent years, notably in the treatment of HIV infections. They work by disabling native protease enzymes and like a key fitting perfectly into a lock, "lock up" the enzyme, rendering it ineffectual

"There could be a number of advantages to taking this approach in attacking inhalational anthrax," notes Cantley. "Unlike an anti-serum, which would require that whole populations be vaccinated -- regardless of whether or not an anthrax outbreak developed -- a therapeutic combination of antibiotics and protease inhibitor drugs wouldn't have to be used except in the incidence of actual disease. This approach would not only reduce the risk of side effects, but could also prove cost effective."

Study coauthors include Robert Liddington, Ph.D., Thiang Yian Wong, Ph.D., and Robert Schwarzenbacher, Ph.D., of The Burnham Institute, La Jolla, California; R. John Collier, Ph.D., of the Department of Microbiology and Molecular Genetics, Harvard Medical School; and Emily Jarrell of BIDMC.

Funding for this study came from the National Institutes of Health, the U.S. National Science Foundation and the U.S. Army.


Story Source:

The above story is based on materials provided by Harvard Medical School. Note: Materials may be edited for content and length.


Cite This Page:

Harvard Medical School. "Anthrax Toxin Inhibitor Identified; Findings Could Lead To More Effective Therapy For Deadly Agent." ScienceDaily. ScienceDaily, 30 December 2003. <www.sciencedaily.com/releases/2003/12/031230015204.htm>.
Harvard Medical School. (2003, December 30). Anthrax Toxin Inhibitor Identified; Findings Could Lead To More Effective Therapy For Deadly Agent. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2003/12/031230015204.htm
Harvard Medical School. "Anthrax Toxin Inhibitor Identified; Findings Could Lead To More Effective Therapy For Deadly Agent." ScienceDaily. www.sciencedaily.com/releases/2003/12/031230015204.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins